ArticleJournal of hepatocellular carcinoma2022

Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.

Ahmed O Kaseb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.